Iron Chelation Therapy Elicits Innate Immune Control of Metastatic Ovarian Cancer

Tito A. Sandoval(Washington University in St. Louis), Juan R. Cubillos‐Ruiz(Cornell University)

Research Square

October 25, 2023

10.21203/rs.3.rs-3399219/v1

Cited by 1

Related Papers

ER Stress Sensor XBP1 Controls Anti-tumor Immunity by Disrupting Dendritic Cell Homeostasis

|Cell|2015|921

IRE1α–XBP1 controls T cell function in ovarian cancer by regulating mitochondrial activity

|Nature|2018|408

Transgelin 2 guards T cell lipid metabolism and antitumour function

|Nature|2024|61

Iron Chelation Therapy Elicits Innate Immune Control of Metastatic Ovarian Cancer

|Cancer Discovery|2024|23

Chemoradiation Reprograms Tumor Cells and the Immune Microenvironment in Cervical Cancer

|Cancer Research|2026|2